203 related articles for article (PubMed ID: 37422621)
21. The impact of obesity and dyslipidemia on Remdesivir effectiveness in hospitalized patients with SARS-CoV-2-related pneumonia: An observational study.
Tumminia A; Romano R; Brugaletta G; Scicali R; Biondi G; Oliveri R; Romano M; San Lio PM
Nutr Metab Cardiovasc Dis; 2022 Jul; 32(7):1635-1641. PubMed ID: 35508458
[TBL] [Abstract][Full Text] [Related]
22. Early 3-day course of remdesivir to prevent progression to severe Covid-19 in high-risk patients with hospital-acquired SARS-CoV-2 infection: preliminary results from two Italian outbreaks.
Meini S; Bracalente I; Bontempo G; Longo B; De Martino M; Tascini C
New Microbiol; 2022 Dec; 45(4):304-307. PubMed ID: 36538294
[TBL] [Abstract][Full Text] [Related]
23. Clinical evolution and mortality of critically ill patients with SARS-CoV-2 pneumonia treated with remdesivir in an adult intensive care unit of Paraguay.
Figueredo J; Lopez LF; Leguizamon BF; Samudio M; Pederzani M; Apelt FF; Añazco P; Caballero R; Bianco H
BMC Infect Dis; 2024 Jan; 24(1):37. PubMed ID: 38166777
[TBL] [Abstract][Full Text] [Related]
24. A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel.
Goldberg E; Ben Zvi H; Sheena L; Sofer S; Krause I; Sklan EH; Shlomai A
Clin Microbiol Infect; 2021 Jun; 27(6):917.e1-917.e4. PubMed ID: 33705849
[TBL] [Abstract][Full Text] [Related]
25. Use of Remdesivir in Patients Hospitalized for COVID-19 Pneumonia: Effect on the Hypoxic and Inflammatory State.
Libra A; Ciancio N; Sambataro G; Sciacca E; Muscato G; Marino A; Vancheri C; Spicuzza L
Viruses; 2023 Oct; 15(10):. PubMed ID: 37896877
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial.
Barratt-Due A; Olsen IC; Nezvalova-Henriksen K; Kåsine T; Lund-Johansen F; Hoel H; Holten AR; Tveita A; Mathiessen A; Haugli M; Eiken R; Kildal AB; Berg Å; Johannessen A; Heggelund L; Dahl TB; Skåra KH; Mielnik P; Le LAK; Thoresen L; Ernst G; Hoff DAL; Skudal H; Kittang BR; Olsen RB; Tholin B; Ystrøm CM; Skei NV; Tran T; Dudman S; Andersen JT; Hannula R; Dalgard O; Finbråten AK; Tonby K; Blomberg B; Aballi S; Fladeby C; Steffensen A; Müller F; Dyrhol-Riise AM; Trøseid M; Aukrust P;
Ann Intern Med; 2021 Sep; 174(9):1261-1269. PubMed ID: 34251903
[TBL] [Abstract][Full Text] [Related]
27. Remdesivir, Renal Function and Short-Term Clinical Outcomes in Elderly COVID-19 Pneumonia Patients: A Single-Centre Study.
Biancalana E; Chiriacò M; Sciarrone P; Mengozzi A; Mechelli S; Taddei S; Solini A
Clin Interv Aging; 2021; 16():1037-1046. PubMed ID: 34113086
[TBL] [Abstract][Full Text] [Related]
28. Experience in the use of remdesivir in patients with SARS-CoV-2 pneumonia.
Murgadella-Sancho A; Gracia-García B; Loureiro-Amigo J; Coloma-Conde A; Losa-López L; Puebla-Villaescusa A
Farm Hosp; 2021 Aug; 45(5):253-257. PubMed ID: 34806585
[TBL] [Abstract][Full Text] [Related]
29. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
Gottlieb RL; Vaca CE; Paredes R; Mera J; Webb BJ; Perez G; Oguchi G; Ryan P; Nielsen BU; Brown M; Hidalgo A; Sachdeva Y; Mittal S; Osiyemi O; Skarbinski J; Juneja K; Hyland RH; Osinusi A; Chen S; Camus G; Abdelghany M; Davies S; Behenna-Renton N; Duff F; Marty FM; Katz MJ; Ginde AA; Brown SM; Schiffer JT; Hill JA;
N Engl J Med; 2022 Jan; 386(4):305-315. PubMed ID: 34937145
[TBL] [Abstract][Full Text] [Related]
30. Early 3-day course of remdesivir in vaccinated outpatients with SARS-CoV-2 infection. A success story.
Panagopoulos P; Petrakis V; Trypsianis G; Papazoglou D
J Chemother; 2022 Dec; 34(8):550-553. PubMed ID: 35838194
[TBL] [Abstract][Full Text] [Related]
31. Remdesivir treatment for patients with moderate to severe COVID-19.
Hasanoğlu İ; Güner R; Çelik İ; Kanat F; Batırel A; Telli GD; Eren E; Yıldız DS; Bozkurt İ; Kart KY; Şenoğlu S; Kazak E; Karaali R; Çelikbaş A; Pullukçu H; Çağatay AA; Ünal S; Erdinç Ş; Tabak F; Gül A; Alp E
Turk J Med Sci; 2022 Aug; 52(4):880-887. PubMed ID: 36326369
[TBL] [Abstract][Full Text] [Related]
32. Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study.
Joo EJ; Ko JH; Kim SE; Kang SJ; Baek JH; Heo EY; Shi HJ; Eom JS; Choe PG; Bae S; Ra SH; Kim DY; Kim BN; Kang YM; Kim JY; Chung JW; Chang HH; Bae S; Cheon S; Park Y; Choi H; Lee E; Lee BY; Park JW; Sohn Y; Heo JY; Kim SH; Peck KR
J Korean Med Sci; 2021 Mar; 36(11):e83. PubMed ID: 33754512
[TBL] [Abstract][Full Text] [Related]
33. Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study.
Benfield T; Bodilsen J; Brieghel C; Harboe ZB; Helleberg M; Holm C; Israelsen SB; Jensen J; Jensen TØ; Johansen IS; Johnsen S; Lindegaard B; Lundgren J; Meyer CN; Mohey R; Pedersen LM; Nielsen H; Nielsen SL; Obel N; Omland LH; Podlekareva D; Poulsen BK; Ravn P; Sandholdt H; Starling J; Storgaard M; Søborg C; Søgaard OS; Tranborg T; Wiese L; Christensen HR
Clin Infect Dis; 2021 Dec; 73(11):2031-2036. PubMed ID: 34111274
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of remdesivir with corticosteroids for COVID-19 patients in intensive care unit: A hospital-based observational study.
Hanafusa M; Nawa N; Goto Y; Kawahara T; Miyamae S; Ueki Y; Nosaka N; Wakabayashi K; Tohda S; Tateishi U; Fujiwara T
J Med Virol; 2023 Jan; 95(1):e28168. PubMed ID: 36148941
[TBL] [Abstract][Full Text] [Related]
35. A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis.
Mehta RM; Bansal S; Bysani S; Kalpakam H
Int J Infect Dis; 2021 May; 106():71-77. PubMed ID: 33647517
[TBL] [Abstract][Full Text] [Related]
36. Remdesivir in kidney transplant patients with SARS-CoV-2 pneumonia.
Cacho J; Burgos E; Molina M; Villegas A; Pérez M; Cañas L; Taco O; Juega J; Lauzurica R
Nefrologia (Engl Ed); 2022; 42(3):311-317. PubMed ID: 36210620
[TBL] [Abstract][Full Text] [Related]
37. Different COVID-19 treatments' impact on hospital length of stay.
Iwamoto S; Muhar BK; Chen H; Chu H; Johnstone M; Sidhu A; Chu H; Fischer J; Chu G
Eur J Med Res; 2023 Jul; 28(1):218. PubMed ID: 37400927
[TBL] [Abstract][Full Text] [Related]
38. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
Ader F; Bouscambert-Duchamp M; Hites M; Peiffer-Smadja N; Poissy J; Belhadi D; Diallo A; Lê MP; Peytavin G; Staub T; Greil R; Guedj J; Paiva JA; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
Lancet Infect Dis; 2022 Feb; 22(2):209-221. PubMed ID: 34534511
[TBL] [Abstract][Full Text] [Related]
39. Clinical outcomes of COVID-19 treated with remdesivir across the continuum of care.
Rivera CG; Chesdachai S; Draper EW; Arndt RF; Mara KC; Gonzalez Suarez M; Razonable RR
Influenza Other Respir Viruses; 2023 May; 17(5):e13136. PubMed ID: 37228805
[TBL] [Abstract][Full Text] [Related]
40. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
